RxDoctor Payments Data

Susan Dallas-Feeney, DO

Family Medicine · West Chester, PANPI 1922187277

Payments from drug & device makers

$5,041in general payments, 2019–2025

Across 300 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$937
  • Novo Nordisk$803
  • Amgen$643
  • AstraZeneca$513
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$355
  • Lilly USA, LLC$320
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$4,92598%
  • Education$1162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,041 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$69,071
Medicare patients
261
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$86,543
MounjaroTirzepatide49$61,597
EliquisApixaban18$18,277
JardianceEmpagliflozin11$14,841
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,628
FarxigaDapagliflozin Propanediol12$11,608
TrulicityDulaglutide13$10,981
SynthroidLevothyroxine Sodium57$7,890
Repatha SureclickEvolocumab11$7,179
EdarbyclorAzilsartan Med/Chlorthalidone17$6,616
Rosuvastatin Calcium249$5,929
Armour ThyroidThyroid,pork27$3,247
TirosintLevothyroxine Sodium16$3,163
Pulmicort FlexhalerBudesonide12$2,990
ValacyclovirValacyclovir Hcl42$2,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$803$86,54365 claims
Lilly USA, LLCMounjaro, Trulicity$320$72,57962 claims
PfizerEliquis$200$18,27718 claims
Boehringer IngelheimJardiance$42$14,84111 claims
AstraZenecaFarxiga, Pulmicort Flexhaler$513$14,59824 claims
GSKTrelegy Ellipta$178$13,62816 claims
AbbVieSynthroid, Armour Thyroid$937$11,13784 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$27$6,61617 claims
IBSA Pharma Inc.Tirosint$59$3,16316 claims
Amneal Pharmaceuticals LLCUnithroid$49$1,11269 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →